• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

评估 BIV1-CovIran 灭活疫苗对新兴 SARS-CoV-2 关切变异株诱导的中和抗体。

Assessment of BIV1-CovIran inactivated vaccine-elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern.

机构信息

Infectious Diseases Department, Tehran University of Medical Sciences, Tehran, Iran.

Center for Research and Training in Skin Disease and Leprosy, Tehran University of Medical Sciences, Tehran, Iran.

出版信息

Clin Microbiol Infect. 2022 Jun;28(6):882.e1-882.e7. doi: 10.1016/j.cmi.2022.02.030. Epub 2022 Mar 3.

DOI:10.1016/j.cmi.2022.02.030
PMID:35248745
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8893932/
Abstract

OBJECTIVES

The BIV1-CovIran vaccine is highly effective against COVID-19. The neutralizing potency of all SARS-CoV-2 vaccines seems to be decreased against variants of concern. We assessed the sensitivity of the Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) variants to neutralizing antibodies (NAbs) present in sera from individuals who had received the BIV1-CovIran candidate vaccine compared with an original Wuhan-related strain.

METHODS

The ability of vaccine serum to neutralize the variants was measured using the conventional virus neutralization test. The correlation of spike (S) protein antibody and anti-receptor binding domain with neutralizing activity was investigated.

RESULTS

The current study demonstrated that 29 of 32 (90.6%; 95% CI: 75.0-98.0) of the vaccinees developed NAbs against a Wuhan-related strain. It is noteworthy that 28 (87.50%) and 24 of 32 (75%) of the recipients were able to produce NAbs against Alpha, Beta, and Delta variants, respectively. Serum virus-neutralizing titres for different SARS-CoV-2 strains were weakly correlated with anti-receptor binding domain antibodies (Spearman r = 36-42, p < 0.05), but not S-binding antibodies (p > 0.05).

DISCUSSION

Although there was a reduction in neutralization titres against the Alpha, Beta, and Delta variants compared with the Wuhan strain, BIV1-CovIran still exhibited potent neutralizing activity against the SARS-CoV-2 variants of concern.

摘要

目的

BIV1-CovIran 疫苗对 COVID-19 具有高度有效性。所有 SARS-CoV-2 疫苗的中和效力似乎都对关注的变体降低了。我们评估了 Alpha（B.1.1.7）、Beta（B.1.351）和 Delta（B.1.617.2）变体对接受 BIV1-CovIran 候选疫苗的个体血清中存在的中和抗体（NAb）的敏感性，与原始与武汉相关的菌株相比。

方法

使用常规病毒中和试验测量疫苗血清中和变体的能力。研究了刺突（S）蛋白抗体和抗受体结合域与中和活性的相关性。

结果

本研究表明，32 名接种者中有 29 名（90.6%；95%CI：75.0-98.0）对武汉相关菌株产生了 NAb。值得注意的是，28 名（87.50%）和 32 名中的 24 名（75%）接受者分别能够产生针对 Alpha、Beta 和 Delta 变体的 NAb。针对不同 SARS-CoV-2 株的血清病毒中和效价与抗受体结合域抗体呈弱相关（Spearman r = 36-42，p < 0.05），但与 S 结合抗体无关（p > 0.05）。

讨论

尽管与武汉株相比，针对 Alpha、Beta 和 Delta 变体的中和效价降低，但 BIV1-CovIran 对关注的 SARS-CoV-2 变体仍表现出强大的中和活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e971/8893932/e19b0d1c3641/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e971/8893932/e38b12ec7fc9/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e971/8893932/f97cb4c3d047/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e971/8893932/b67984f79f96/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e971/8893932/e19b0d1c3641/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e971/8893932/e38b12ec7fc9/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e971/8893932/f97cb4c3d047/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e971/8893932/b67984f79f96/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e971/8893932/e19b0d1c3641/gr3_lrg.jpg

相似文献

1
Assessment of BIV1-CovIran inactivated vaccine-elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern.评估 BIV1-CovIran 灭活疫苗对新兴 SARS-CoV-2 关切变异株诱导的中和抗体。
Clin Microbiol Infect. 2022 Jun;28(6):882.e1-882.e7. doi: 10.1016/j.cmi.2022.02.030. Epub 2022 Mar 3.
2
Safety and potency of BIV1-CovIran inactivated vaccine candidate for SARS-CoV-2: A preclinical study.用于 SARS-CoV-2 的 BIV1-CovIran 灭活候选疫苗的安全性和效力：一项临床前研究。
Rev Med Virol. 2022 May;32(3):e2305. doi: 10.1002/rmv.2305. Epub 2021 Oct 26.
3
Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay.针对 SARS-CoV-2 武汉-Hu-1 株及其关注变异株的中和活性的比较分析：基于假病毒的中和测定的性能评估。
Front Immunol. 2022 Sep 26;13:981693. doi: 10.3389/fimmu.2022.981693. eCollection 2022.
4
A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.一种糖基化 RBD 蛋白诱导针对奥密克戎和其他变体的增强型中和抗体，提高对 SARS-CoV-2 感染的保护作用。
J Virol. 2022 Sep 14;96(17):e0011822. doi: 10.1128/jvi.00118-22. Epub 2022 Aug 16.
5
Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.三种原型株衍生重组蛋白疫苗对 B.1.1.7、B.1.351 和 B.1.617.1 变异 SARS-CoV-2 诱导产生广谱中和抗体。
Viruses. 2021 Jul 22;13(8):1421. doi: 10.3390/v13081421.
6
Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time.卫星五号疫苗接种后的纵向研究显示，随着时间的推移，SARS-CoV-2 中和抗体具有持久性，并且对病毒变异的中和逃逸能力降低。
mBio. 2022 Feb 22;13(1):e0344221. doi: 10.1128/mbio.03442-21. Epub 2022 Jan 25.
7
Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees.奥密克戎 BA.1 和 BA.2 中和抗体在 COVID-19 mRNA 疫苗接种者中的结构分析。
Nat Commun. 2022 Jun 13;13(1):3375. doi: 10.1038/s41467-022-31115-8.
8
Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination.感染和接种后对 SARS-CoV-2 的异源中和活性。
Front Immunol. 2022 May 30;13:888794. doi: 10.3389/fimmu.2022.888794. eCollection 2022.
9
The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice.SARS-CoV-2 刺突蛋白亚单位疫苗中的 E484K 取代导致小鼠产生有限的交叉反应性中和抗体反应。
Viruses. 2022 Apr 21;14(5):854. doi: 10.3390/v14050854.
10
Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.mRNA 疫苗接种后针对 SARS-CoV-2 变体 RBD 的中和抗体反应减弱和异质性。
Front Immunol. 2022 Apr 6;13:816389. doi: 10.3389/fimmu.2022.816389. eCollection 2022.

引用本文的文献

1
Prediction of hospitalization time probability for COVID-19 patients with statistical and machine learning methods using blood parameters.使用血液参数，通过统计和机器学习方法预测新冠病毒肺炎患者的住院时间概率
Ann Med Surg (Lond). 2024 Sep 4;86(12):7125-7134. doi: 10.1097/MS9.0000000000002477. eCollection 2024 Dec.
2
Stability of Neutralizing Antibody of PastoCoAd Vaccine Candidates against a Variant of Concern of SARS-CoV-2 in Animal Models.在动物模型中 PastoCoAd 候选疫苗对 SARS-CoV-2 关注变体的中和抗体稳定性。
Iran Biomed J. 2024 Jul 1;28(4):214-20. doi: 10.61186/ibj.3980.
3
COVID-19 Incidence Proportion as a Function of Regional Testing Strategy, Vaccination Coverage, and Vaccine Type.

本文引用的文献

1
SARS-COV-2 Variants: Differences and Potential of Immune Evasion.SARS-CoV-2 变异株：免疫逃逸的差异和潜力。
Front Cell Infect Microbiol. 2022 Jan 18;11:781429. doi: 10.3389/fcimb.2021.781429. eCollection 2021.
2
SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo.严重急性呼吸综合征冠状病毒2型奥密克戎变异株在人支气管和肺组织外植体中的复制
Nature. 2022 Mar;603(7902):715-720. doi: 10.1038/s41586-022-04479-6. Epub 2022 Feb 1.
3
SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells.
COVID-19 发病率与区域检测策略、疫苗接种覆盖率和疫苗类型的关系。
Viruses. 2023 Oct 30;15(11):2181. doi: 10.3390/v15112181.
4
The protection quest is a primary key to sharing the neutralizing antibody response to cover against all emerging VOCs based on BIV1-CovIran studies.基于BIV1-CovIran研究，寻求保护是共享中和抗体反应以抵御所有新出现的变异株的关键。
Heliyon. 2023 Mar;9(3):e14108. doi: 10.1016/j.heliyon.2023.e14108. Epub 2023 Feb 26.
5
COVID-19 vaccines and a perspective on Africa.COVID-19 疫苗和非洲视角。
Trends Immunol. 2023 Mar;44(3):172-187. doi: 10.1016/j.it.2023.01.005. Epub 2023 Jan 11.
6
Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体与疫苗效力
Vaccines (Basel). 2022 Oct 19;10(10):1751. doi: 10.3390/vaccines10101751.
与德尔塔变异株相比，SARS-CoV-2 奥密克戎变异株在表达 TMPRSS2 的细胞中的复制和融合活性较低。
Emerg Microbes Infect. 2022 Dec;11(1):277-283. doi: 10.1080/22221751.2021.2023329.
4
Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective.新型关注变异株 SARS-CoV-2 奥密克戎（B.1.1.529）的特征及其全球视角。
J Med Virol. 2022 Apr;94(4):1738-1744. doi: 10.1002/jmv.27524. Epub 2022 Jan 11.
5
The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines.SARS-CoV-2 变异株的出现威胁到中和抗体和疫苗的效力。
Biochem Soc Trans. 2021 Dec 17;49(6):2879-2890. doi: 10.1042/BST20210859.
6
Safety and potency of BIV1-CovIran inactivated vaccine candidate for SARS-CoV-2: A preclinical study.用于 SARS-CoV-2 的 BIV1-CovIran 灭活候选疫苗的安全性和效力：一项临床前研究。
Rev Med Virol. 2022 May;32(3):e2305. doi: 10.1002/rmv.2305. Epub 2021 Oct 26.
7
COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants.COVID-19 疫苗：紧跟 SARS-CoV-2 变异株。
Cell. 2021 Sep 30;184(20):5077-5081. doi: 10.1016/j.cell.2021.09.010. Epub 2021 Sep 17.
8
Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers.接种 BNT162b2 疫苗 3 个月后抗 SARS-CoV-2 抗体反应的动力学；283 名卫生工作者的前瞻性研究。
Cells. 2021 Jul 30;10(8):1942. doi: 10.3390/cells10081942.
9
Correlation between a quantitative anti-SARS-CoV-2 IgG ELISA and neutralization activity.抗 SARS-CoV-2 IgG ELISA 定量检测与中和活性的相关性。
J Med Virol. 2022 Jan;94(1):388-392. doi: 10.1002/jmv.27287. Epub 2021 Aug 31.
10
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.BNT162b2疫苗对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异株B.1.617.2和B.1.351的中和抗体活性
Lancet. 2021 Jun 19;397(10292):2331-2333. doi: 10.1016/S0140-6736(21)01290-3. Epub 2021 Jun 3.